Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2003-02-20
2008-10-21
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S388240, C530S391100, C530S391300, C530S391700, C435S007100, C435S810000, C435S975000, C424S145100
Reexamination Certificate
active
07438908
ABSTRACT:
A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
REFERENCES:
patent: 4687732 (1987-08-01), Ward
patent: 5482698 (1996-01-01), Griffiths
patent: 5624659 (1997-04-01), Bigner et al.
patent: 5820858 (1998-10-01), Leturcq
patent: 6335014 (2002-01-01), Kusakabe
patent: WO03075960 (2003-09-01), None
Balza E et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 332:39-43 (1993).
Balza et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS 332:39-43, 1993.
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Paganelli et al; “Antibody-Guided Three-Step Therapy for High Grade Glioma With Yttrium-90 Biotin”; European Journal of Nuclear Medicine 1999, Germany, vol. 26, No. 4, 1999, pp. 348-357, XP008019281.
Prashanta et al; “Tenascin in Human Neoplasia: Immunohistochemical Observations Using Seven Different Clones of Monoclonal Antibodies”; International Journal of Oncology, vol. 8, No. 4, 1996, pp. 741-755, XP008019285.
De Santis et al; “Novel Antitenascin Antibody With Increased Tumor Localisation for Pretargeted Antibody-Guided Radioimmunotherapy (PAGRIT)”; British Journal of Cancer, England, Apr. 7, 2003, vol. 88, No. 7,pp. 996-1003, XP008019208.
Chinol et al, “Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity”, British Journal of Cancer, vol. 78, No. 2, Jul. 1998, pp. 189-197.
Reznik et al, “Streptavidins with intersubunit crosslinks have enhanced stability”, Nature Biotechnology, Nature Publishing, US, vol. 14, Aug. 1998, pp. 1007-1011.
Chinol et al—Biodistribution in tumour-bearing mice of Two 90Y-labelled biotins using three-step tumour targeting, Nuclear Medicine Communications, 1997, 18, pp. 176-182.
Cremonesi et al, “Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients”, European Journal of Nuclear Medicine, vol. 26, No. 2, Feb. 1999, pp. 110-120.
Hart et al, “HPMA copolymer-modified avidin: Immune response”, Journal of Biomaterials Science, Polymer Edition, vol. 11, No. 1, 2000, pp. 1-12.
File History of U.S. Appl. No. 10/506,159 obtained from U.S. PTO IFW on Jun. 21, 2007.
Anastasi Anna Maria
De Santis Rita
Haddad Maher M
Nixon & Vanderhye P.C.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Anti-human tenascin monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-human tenascin monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human tenascin monoclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013729